Key facts
- This page summarizes Adimab, LLC's Form 4 filing for Invivyd, Inc. (IVVD).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 22 Jan 2024, 16:18.
Adimab, LLC - 19 Jan 2024 Form 4 Insider Report for Invivyd, Inc. (IVVD)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- IVVD
- Reported as of
- 19 Jan 2024
- Net transaction value
- -$19,750,000
- SEC form
- 4
- Accepted by SEC
- 22 Jan 2024, 16:18:16 UTC
- Prior SEC filing
- 01 Apr 2022
- Source filing
- View source filing
- Reporting owner signature
- By: /s/ Philip Chase, Chief Executive Officer
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Adimab, LLC filed Form 4 for Invivyd, Inc. (IVVD) on 22 Jan 2024.
Change
- Previous filing in this sequence was filed on 01 Apr 2022.
- Current net transaction value: -$19,750,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IVVD
transaction
Common Stock
Sale
- Transaction value
- $19,750,000
- Shares
- -5,000,000
- Change %
- -19%
- Price
- $3.95
- Shares after
- 21,687,906
- Date
- 19 Jan 2024
- Ownership
- Direct
* marks a reported price that did not pass the local price check.